BONESUPPORT’s corporate governance is governed by the Swedish Companies Act and other applicable laws and regulations, the company’s articles of association, the Swedish Corporate Governance Code, Nasdaq’s Rule Book for Issuers, good practice in the stock market, internal policy documents and other applicable rules and recommendations. Deviations from the Swedish Corporate Governance Code, if any, will be reported annually in the company’s corporate governance report.
The Board
According to BONESUPPORT’s articles of association, the board of directors, to the extent appointed by the general meeting, shall consist of no less than three and no more than eight members. BONESUPPORT’s board of directors currently consists of five board members appointed by the general meeting on 17 May 2023 for the period until the end of the annual general meeting to be held in 2024.
LENNART JOHANSSON
CHAIRMAN OF THE BOARD
Born 1955. Member of the Board of Directors since 2017 and chairman since 2019.
Lennart Johansson has been Senior Advisor for Patricia Industries AB since 2015 and was previously Managing Director (Business Development, Operational and Financial Investments) at Investor AB (2006-2015). Prior to that, he was a partner and CEO of Emerging Technologies ET AB and b-business partners. Today he is a Board member of Chalmers Ventures AB, Hi3G Access AB, Atlas Antibodies AB and GoCo Development AB.
Lennart Johansson holds an MBA from Handelshögskolan, Stockholm (1980).
Independent in relation to the Company and its management and in relation to major shareholders.
September 30, 2023: Holdings: 105,200 shares (own holding).
HÅKAN BJÖRKLUND
BOARD MEMBER
Born 1956. Chairman of the board of directors from 2016 to 2019.
Dr. Björklund is Partner of Tellacq AB, a private investment firm. He joined the BONESUPPORT Board in December 2016 in conjunction with the Company’s $37 million (SEK 315 million) financing, which was led by Tellacq. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners. He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.
September 30, 2023: Holdings: owns 25% of the shares in Tellacq AB, which holds 1.180.976 shares.
BJÖRN ODLANDER
BOARD MEMBER
Born 1958. Member of the board of directors since 2010.
M.D, Ph.D, Karolinska Institute in Stockholm
A founding partner of HealthCap. Dr. Odlander is a Medical Doctor and was previously a member of ABB Aros Management Committee and headed the Aros Health Care Team. Prior to joining Aros in 1992, Dr. Odlander was active at the Karolinska Institute, Stockholm, Sweden. In addition to teaching medical students, he pursued scientific research in the biochemistry of inflammation. Dr. Odlander serves on the boards of the following companies; among others: Cardoz AB, OxThera AB, LTB4 Sweden AB and Nordic Nanovector AS.
Independent in relation to the Company and its management, but not in relation to major shareholders. Partner in HealthCap and board member in several companies in the HealthCap group.
September 30, 2023: Holdings: -
CHRISTINE RANKIN
BOARD MEMBER
Christine Rankin holds a bachelor's degree in business administration and economics from Stockholm University. Currently, Christine Rankin is a board member of Coinshares International Ltd. and Senior Vice President Corporate Control at Veoneer Inc. Christine Rankin has previously been a board member of Adventure Box Technology AB, board member of Technopolis Plc, CFO at Cherry AB, acting CFO/Head of Finance at Serneke Group, Head of Corporate Control at Spotify and partner/Head of US Capital Markets in Sweden at PwC.
September 30, 2023: Holdings: 1.395 shares (own holding)
MARY I O’CONNOR
BOARD MEMBER
Mary I O’Connor, MD, is Professor Emerita of Orthopedic Surgery at Mayo Clinic and Past Professor of Orthopaedics and Rehabilitation at Yale University School of Medicine. In 2021 she became co-founder and Chief Medical Officer at Vori Health, a physician-led virtual musculoskeletal company. Dr. O’Connor is a nationally recognized leader in health equity, chairing the Movement is Life Caucus, a nonprofit multi-stakeholder coalition committed to addressing musculoskeletal health disparities, since its inception in 2010.
September 30, 2023: Holdings: till 18 883 shares (own holding)
Management Team
EMIL BILLBÄCK
CHIEF EXECUTIVE OFFICER
Emil Billbäck has more than 20 years’ experience in commercial operations within the life science industry - 11 years of which gained in senior leadership positions under private equity ownership (Montagu and EQT). Most recently, he was Senior Advisor to the recently merged BSN medical/ SCA entity. Before the merger he was Executive Vice President EMEA and Head of Global Commercial Operations, at BSN medical. Prior to this Emil held several roles at BSN medical as Interim President North America, Group Director Commercial Operations, Group Director R&D and President APAC. Before joining BSN medical, Emil worked at Beiersdorf and AstraZeneca. While Swedish native, Emil has lived and worked 4 years in the US and more than 9 years in Germany. He holds a BSc in Business Administration from Karlstad University.
September 30, 2023: Holdings: 454.425 shares (own holding)
HÅKAN JOHANSSON
CHIEF FINANCIAL OFFICER
Håkan Johansson joined BONESUPPORT as Chief Financial Officer in November 2018. He has more than 20 years' of experience gained from CFO and Senior Management roles in various industries in public and private companies. Prior to joining BONESUPPORT he was CFO Northern Europe within Tunstall Healthcare Group (2012-18), a global provider of connected health and connected care solutions. Before this he held CFO and Senior Management roles at toy manufacturer BRIO AB (publ) and Arctic Paper Group. Mr Johansson holds a BSc in Business Administration & Economics from the Mid-Sweden University.
September 30, 2023: Holdings: 55.184 shares (own holding)
KRISTINA INGVAR
EVP QUALITY MANAGEMENT & REGULATORY AFFAIRS
Kristina Ingvar has overall responsibility for global quality and regulatory compliance at BONESUPPORT. She joined as Executive Vice President Quality Management & Regulatory Affairs in February 2020, bringing more than 20 years of life science experience from areas across the value chain, in both large and small companies. Prior to joining BONESUPPORT, Kristina spent almost 13 years with Novo Nordisk, most recently in a role as Global Program Vice President, Global Regulatory Affairs. She has held various other product-, project- and people management positions in the regulatory, quality, safety and medical areas. She holds a Bachelor of Medicine and a Diploma in Marketing Management, with additional studies in Public Health.
September 30, 2023: Holdings: 35.606 shares (own holding)
MICHAEL DIEFENBECK
EVP MEDICAL & CLINICAL AFFAIRS CHIEF MEDICAL OFFICER
Dr. Diefenbeck joined BONESUPPORT AB in April 2017. In 2014 he founded Scientific Consulting in Orthopaedic Surgery and worked for BONESUPPORT AB on different projects as an independent clinical advisor. He is currently honorary consultant at Nuffield Orthopaedic Centre, Oxford University Hospitals. Dr. Diefenbeck studied medicine at Munich and was trained as an orthopaedic surgeon, specializing in trauma care and bone infections. He has 14 years’ clinical experience at different German hospitals (BG Unfallklinik Murnau, BG Kliniken Bergmannstrost Halle/Saale, University Hospital Jena and Schön Klinik Hamburg Eilbek). At University Hospital Jena he finished his PhD in 2011 and has since been involved in surgical education and training programs for students. He is author of 24 Pub-med listed research articles.
September 30, 2023: Holdings: 121.160 shares (own holding) and 360.000 employee stock options, which can be converted to 72.000 shares.
FERGUS MACLEOD
GM & EVP COMMERCIAL OPERATIONS EUROW
Fergus MacLeod joined BONESUPPORT as General Manager & Executive Vice President responsible for Commercial Operations across EUROW in November 2019. Fergus has a proven track record in senior, international medical device leadership roles in a career spanning over 20 years. Most recently, Fergus has held General Management responsibility for the Global Medical Device assets at Johnson Matthey, a publicly traded British company and previously as Vice President & Managing Director with responsibility for Commercial Operations across EMEA for RTI Surgical, an international Medical Device and Orthobiologics company and over eight years at Stryker in roles of increasing responsibility. Fergus over his career has acquired extensive experience in building and leading high performing teams and commercializing medical technologies. Fergus has recently completed an Executive Leadership program at the Center for Creative Leadership and holds a HND in Business & Finance from the University of Bedfordshire.
September 30, 2023: Holdings: 23 900 shares (own holding)
MIKE ROTH
GM & EVP COMMERCIAL OPERATIONS NORTH AMERICA
Michael Roth joined BONESUPPORT as the General Manager and Executive Vice President Commercial Operations for North America in June 2020. Michael has over 25 years of direct and distributor-based sales, marketing and sales leadership experience within the orthopaedic market sector for both large and small companies. Most recently, he was Vice President of Sales and Marketing for Surgical Planning Associates (HipXpert) where he led the strategic initiative to refine the marketing strategy, increase commercial brand visibility and grow sales. He also held Vice President of Sales positions in the east region with both Wright Medical and Microport Orthopaedics where he had a sustained track record of building strong sales networks, developing dynamic management teams and cultivating a high-performance sales culture in the competitive large joint, foot and ankle and orthobiologic market segments. Mr. Roth holds a bachelor degree in International Development from Clark University.
September 30, 2023: Holdings: 20.000 shares (own holding)
HELENA BRANDT
EVP HUMAN RESOURCES
Helena L Brandt is a senior HR leader with more than 20 years’ experience gained from a broad range of industries, from life science to IT/Telecom and more. Helena has held global HR leadership roles at Astra Zeneca, Sony and Tetra Pak, developing organizations, people, leaders, teams and culture as well as driving transformation and change. She holds an International Business & Economics Master’s Degree from Lund University, Sweden, and also studied at the University of Cologne in Germany and at the universities of Cincinnati and Delaware in the U.S.
September 30, 2023: Holdings: 20.000 shares (own holding)
Annelie Aava Vikner
EVP GLOBAL MARKETING
Annelie Aava Vikner joined BONESUPPORT as Executive Vice President Global in March 2019. Mrs Aava Vikner has more than 25 years’ of experience from marketing, sales and clinical trials in the field of medical technology & pharma. Before joining BONESUPPORT she worked at Medtronic in different regional leading positions, mainly within marketing. Mrs Aava Vikner holds a bachelor degree in Chemistry from the Linköping institute of technology, LIU (Linköping University) and a post graduate certificate in Leadership from Glasgow Caledonian University.
September 30, 2023: Holdings: 14.480 shares (own holding)
MICHAEL WRANG MORTENSEN
EVP R&D AND OPERATIONS
Michael Wrang Mortensen joined BONESUPPORT in December 2021 as Executive Vice President with the overall responsibility for R&D and Operations. Michael has 15 years of experience from the Medical Device and Healthcare industry with solid leadership and management experience within Innovation, Product Realization, Commercial Development and Operations. Prior to joining BONESUPPORT Michael was Director for Development and Supply at Nanovi A/S. Before this Michael held various management positions at Ferrosan Medical Devices A/S innovating and developing combination products in partnership with large global players such as Ethicon Biosurgery Inc, Johnson and Johnson. Michael holds a MSc in Engineering from Technical University of Denmark, a PhD in Chemistry from University of Copenhagen and an executive MBA from the AVT Business School in Denmark.
September 30, 2023: Holdings: 13 000 shares (own holding)
Audit Committee
The audit committee’s role is mainly to monitor the BONESUPPORT’s financial position, to monitor the effectiveness of the company’s internal control, internal audit and risk management, to be informed about the audit of the annual report and consolidated financial statements, and to review and monitor the auditor’s impartiality and independence. The audit committee shall also assist the nomination committee in proposals for decisions on the election and remuneration of the auditor. After the annual general meeting on 17 May 2023, the audit committee is comprised of Christine Rankin (chairman) and Lennart Johansson.
CHRISTINE RANKIN
CHAIRMAN
Christine Rankin holds a bachelor's degree in business administration and economics from Stockholm University. Currently, Christine Rankin is a board member of Coinshares International Ltd. and Senior Vice President Corporate Control at Veoneer Inc. Christine Rankin has previously been a board member of Adventure Box Technology AB, board member of Technopolis Plc, CFO at Cherry AB, acting CFO/Head of Finance at Serneke Group, Head of Corporate Control at Spotify and partner/Head of US Capital Markets in Sweden at PwC.
LENNART JOHANSSON
CHAIRMAN OF THE BOARD
Lennart Johansson has been Senior Advisor for Patricia Industries AB since 2015 and was previously Managing Director (Business Development, Operational and Financial Investments) at Investor AB (2006-2015). Prior to that, he was a partner and CEO of Emerging Technologies ET AB and b-business partners. Today he is a Board member of Chalmers Ventures AB, Hi3G Access AB, Atlas Antibodies AB and GoCo Development AB.
Lennart Johansson holds an MBA from Handelshögskolan, Stockholm (1980).
Remuneration Committee
The remuneration committee’s role is primarily to prepare matters regarding remuneration and other terms of employment for the CEO and senior executives. The remuneration committee shall also monitor and evaluate ongoing and completed programs for variable remuneration to BONESUPPORT’s senior executives and to monitor and evaluate the implementation of the guidelines for remuneration to senior executives which the annual general meeting has adopted. After the annual general meeting on 17 May 2023, the remuneration committee is comprised of Håkan Björklund, Björn Odlander, and Lennart Johansson (chairman).
BJÖRN ODLANDER
BOARD MEMBER
Born 1958. Member of the board of directors since 2010.
M.D, Ph.D, Karolinska Institute in Stockholm
A founding partner of HealthCap. Dr. Odlander is a Medical Doctor and was previously a member of ABB Aros Management Committee and headed the Aros Health Care Team. Prior to joining Aros in 1992, Dr. Odlander was active at the Karolinska Institute, Stockholm, Sweden. In addition to teaching medical students, he pursued scientific research in the biochemistry of inflammation. Dr. Odlander serves on the boards of the following comapanies; among others: Cardoz AB, OxThera AB, LTB4 Sweden AB and Nordic Nanovector AS.
HÅKAN BJÖRKLUND
BOARD MEMBER
Born 1956. Chairman of the board of directors from 2016 to 2019.
Dr. Björklund is Partner of Tellacq AB, a private investment firm. He joined the BONESUPPORT Board in December 2016 in conjunction with the Company’s $37 million (SEK 315 million) financing, which was led by Tellacq. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners. He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.
LENNART JOHANSSON
CHAIRMAN OF THE BOARD
Born 1955. Member of the Board of Directors since 2017 and chairman since 2019.
Lennart Johansson has been Senior Advisor for Patricia Industries AB since 2015 and was previously Managing Director (Business Development, Operational and Financial Investments) at Investor AB (2006-2015). Prior to that, he was a partner and CEO of Emerging Technologies ET AB and b-business partners. Today he is a Board member of Chalmers Ventures AB, Hi3G Access AB, Atlas Antibodies AB and GoCo Development AB.
Lennart Johansson holds an MBA from Handelshögskolan, Stockholm (1980).
Remuneration Principles
Remuneration to the board of directors
Fees to board members elected by the general meeting are resolved by the annual general meeting. For the annual general meeting on 17 May 2023, the nomination committee submitted proposals in regard to remuneration.
Remuneration to senior executives
According to the Swedish Companies Act, the general meeting shall determine the guidelines for remuneration to the CEO and other senior executives. At the annual general meeting held on 17 May 2023, guidelines were adopted with the following main content.
The Company’s starting point is to offer remuneration levels at market terms, aimed at facilitating the recruitment and retention of senior executives, and that the terms should be competitive considering the situation in the country in which the employee is employed. The remuneration to the senior executives can be comprised of fixed salary, variable cash, pension benefits and other benefits.
The fixed salary shall take into consideration the individual’s competence, area of responsibility and performance. The variable cash is to be based on the outcome of predetermined well defined objectives. The variable cash remuneration is to be limited and may not exceed 75 per cent of the fixed annual salary for the CEO, 52.5 per cent of the fixed annual salary for the CFO and 40 per cent of the fixed annual salary for other senior executives, whereby the individual highest level should be based on factors such as the position held by the specific individual.
Pension benefits, including health insurance, shall be defined contribution, insofar as the senior executive is not covered by defined benefit pension under mandatory collective bargaining agreements. Premiums for defined contribution pensions, including health insurance, may amount to a maximum of 40 per cent of the fixed annual salary.
The senior executives may be awarded other customary benefits, such as a company car, occupational health services, etc.
Upon termination of an employment by the Company, the notice period may not exceed twelve months. Severance pay, in addition to fixed salary and other remuneration during the notice period, may not exceed an amount corresponding to the fixed annual cash salary for twelve months. Upon termination by the senior executive, the notice period may not exceed six months.
The board of directors may temporarily resolve to deviate from these guidelines, in whole or in part, if in a specific case there is a special cause for the deviation and a deviation is necessary to serve the Company’s long-term interests.
Incentive Programs
BONESUPPORT has two employee stock option programs and three performance share programs.
Employee stock options programs
Of the two employee stock option programs, one runs over ten years and expires 2025 and one program runs over eight years and expires 2024. Each stock option gives the holder the right to acquire 0.2 ordinary shares in BONESUPPORT when exercising the option. This at a price in the first program of SEK 0.125 per option, equivalent to SEK 0.625 per share, and in the second program of SEK 5.30 per option, equivalent to SEK 26.50 per share. The employee stock options are vested according to a schedule in each program. A condition for allotment of options is employment or a contractual relationship with the Company at each vesting date. Of the previously allocated 25.7 million options, 8.9 million options regard active programs. Of these 8.9 million options, 5.2 million options were fully vested before September 30, 2023. Remaining 3.7 million options were not allocated.
Performance share programs
There are two programs for employees and one program for one board member.
The programs run as follows with the below end dates:
– The program for employees decided at the annual general meeting in 2020 runs until 31 December 2023;
– The program for employees decided at the annual general meeting in 2021 runs until 31 December 2023; and
– The program for one Board member decided at the Annual General Meeting in 2021 runs until the date of the annual general meeting in 2024.
In the program for employees decided at the Annual General Meeting in 2020, each savings share gives the opportunity to be allotted to the employees a maximum of two or three performance shares without payment depending on share price development and the Company’s development in terms of sales and EBITDA during the duration of the program. The performance shares were issued in the form of class C-shares with a subscription price and quota value of SEK 0.625 per share.
In the program for employees decided at the Annual General Meeting in 2021, each savings share gives the opportunity to be allotted a maximum of six performance shares without payment depending on share price development and the company’s development in terms of sales and EBITDA during the duration of the program.
In the program for one Board member decided at the Annual General Meeting in 2021, each savings share gives the opportunity to be allotted a maximum of three performance shares without payment depending on share price development.
The Annual General Meeting in May 2022 authorized the Board to issue C-shares to cover social security charges for the latest programs. The mandate from the Annual General Meeting was fulfilled during 2022. The mandate to issue C-shares enabled the close of the share swap that was entered into during 2021.
Employee stock options and performance shares are valued at fair value at the date of allocation. The total cost is distributed over the vesting period. The cost is accounted for as personnel cost and is credited to equity. The social security cost is revalued at fair value. When the options are exercised, the company issues new shares. Payments received on behalf of the shares issued are credited to equity.
Further information on these programs is presented in Notes 12 and 23 in the Annual Report 2022.
| Employee stock option programs |
No of options[1] |
Equal to no of shares |
WAEP[2] |
| Balance January 1, 2023 | 420 208 | 84 044 | 26,50 |
| Exercised | -5 000 | -1 000 | 26,50 |
| Balance September 30, 2023 | 415 208 | 83 044 | 26,50 |
| Performance share programs |
|
|
Right to no of shares |
| Balance January 1, 2023 |
1 323 000 |
||
| Distributed regarding completed program |
-500 378 |
||
| Cancelled during the year | -130 622 | ||
| Balance September 30, 2023 | 692 000 | ||
[1] Not allocated options amounted to 3,699,047.
[2] Weighted Average Exercise Price per share (SEK).
Auditors
Ernst & Young AB with Henrik Rosengren as auditor in charge.
Corporate Governance Reports
The Corporate Governance Reports are included in the Annual Report.
Nomination Committee
According to the Swedish Corporate Governance Code, BONESUPPORT HOLDING AB (publ) shall have a Nomination Committee, the duties of which shall include preparation and drafting of proposals regarding the election of members of the Board of Directors, the Chairman of the Board of Directors, the Chairman of the General Meeting and Auditors. The Nomination Committee shall also propose fees for Board members and the Auditor and principles for the appointment of the Nomination Committee. At the Annual General Meeting on 17 May 2023, it was resolved to adopt an instruction for the Nomination Committee according to which the Nomination Committee shall consist of three members, representing the three largest shareholders as per 30 September of each calendar year. The chairman of the board is responsible to convene the Nomination Committee to its first meeting, and shall also be co-opted to the Nomination Committee, except when the Nomination Committee shall address to the matter of chairman of the board and remuneration to the chairman of the board.
The Nomination Committee for the 2024 Annual General Meeting consists of Staffan Lindstrand, appointed by HealthCap V LP, Caroline Sjösten, appointed by Swedbank Robur fonder, and Jan Särlvik, appointed by Fjärde AP-fonden (AP4). In addition, Lennart Johansson, is co-opted to the Nomination Committe as chairman of the Board of Directors. The Nomination Committee will appoint a committee chair at its first meeting.
Proposals to the Nominating Committee should be addressed to BONESUPPORT HOLDING AB, Att: Nomination Committee, Scheelevägen 19, Ideon Science Park, SE-223 70 Lund, Sweden or by email to .
General Meetings
General meetings shall be held in Lund. Notice convening the annual general meetings and extraordinary general meetings where amendments to the articles of association are to be addressed, shall be issued no earlier than six weeks and no later than four weeks prior to the meeting. Notice convening other extraordinary general meetings shall be issued no earlier than six weeks and no later than three weeks prior to the meeting. Notice shall be published in the Swedish National Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the company’s website. Information regarding the notice shall at the same time be advertised in Svenska Dagbladet.
The 2024 Annual General Meeting will be held on May 16, 2024 in Lund.
Proposals to the General Meeting should be addressed to BONESUPPORT HOLDING AB, Att: Legal, Scheelevägen 19, Ideon Science Park, SE-223 70 Lund, Sweden or by email to and submitted no later than seven weeks prior to the Annual General Meeting to ensure that the request can be considered.
AGM 2023
Minutes AGM 2023
Notice Annual General Meeting 2023
Power of Attorney Annual General Meeting 2023
Board statement pursuant to Chapter 19, Section 22 of the Swedish Companies Act 2023
Board proposal on authorization regarding issues 2023
Board proposal on authorization regarding transfer of own shares 2023
Board proposal on share saving program for employees 2023
Nomination Committees proposal on instruction for the Nomination Committee 2023
The Nomination Committees proposals and reasoned statement 2023
Board proposal on guidelines for remuneration to senior executives 2023
Auditor statement pursuant to ch 8 sec 54 of the Swedish Companies Act 2023
Remuneration report 2022
AGM 2022
Minutes AGM 2022
Notice Annual General Meeting 2022
Power of Attorney AGM 2022
Statement of the board of directors pursuant to Chapter 19, Section 22 of the Swedish Companies Act 2022
The board_s proposal on authorization regarding issues 2022
The boards proposal on issues and repurchase of series C shares and transfer of own shares 2022
The Nomination Committee's proposal for new board members 2022
The Nomination Committees proposals and reasoned statement 2022
Auditor's opinion on guidelines regarding remuneration to Group Executive Management
Remuneration report 2021
AGM 2021
AGM Minutes 2021
Auditor's opinion on guidelines regarding remuneration to Group Executive Management
Notice Annual General Meeting
Postal voting form
Power of Attorney
Statement of the board of directors pursuant to Chapter 19, Section 22 of the Swedish Companies Act
The board's proposal on amendment of the Articles of Association
The board's proposal on share saving program for senior executives and other key employees
The Nomination Committee's proposal on share saving program for certain board members
The Nomination Committee's proposals and reasoned statement and instruction
Remuneration report 2020
Instruction for the Nomination Committee
AGM 2020
Minutes from the Annual Shareholders Meeting
Notice Annual General Meeting
Auditor's opinion on guidelines regarding remuneration to Group Executive Management
Report by the board on remuneration principles
Statement of the board of directors pursuant to Chapter 19, Section 22 of the Swedish Companies Act
Template Power of Attorney
The board's proposal on amendment of the Articles of Association
The board's proposal on authorization regarding issues
The board's proposal on guidelines for remuneration to senior executives
The board's proposal on share saving program for employees
The Nomination Committee's proposals and reasoned statement
AGM 2019
Minutes from the annual shareholders meeting
Auditor's Opinion
Notice AGM 2019
The Nomination Committee’s proposals and reasoned statement
Report by the board of directors on remuneration principles
The board of directors proposal on Remuneration Policy
The board of directors proposal on share saving program for employees
Statement of the board of directors pursuant to Chapter 19, Section 22 of the Swedish Companies Act
Power of Attorney template
AGM 2018
Notice AGM 2018
The Nomination Committee’s proposals and reasoned statement
Report by the board of directors on programs for variable remuneration
The board of directors proposal on Remuneration Policy
The board of directors proposal on long-term incentive program for senior executives
The board of directors proposal on amendment of the Articles of Association
The board of directors proposal on share saving program for employees
The Nomination Committee’s proposal on share saving program for certain members of the board of directors
Statement of the board of directors pursuant to Chapter 19, Section 22 of the Swedish Companies Act
Power of Attorney template
Auditor’s report in accordance with Chapter 8, Section 54 of the Swedish Companies Act
BONESUPPORT HOLDING AB - unofficial translation of the minutes from the annual shareholders meeting 2018